Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
Enveric Biosciences, Inc. has called its 2026 annual stockholder meeting for May 28, 2026 at 10:00 a.m. Eastern Time, to be held exclusively online via live webcast. Stockholders of record as of March 30, 2026, when 1,887,535 shares of common stock were outstanding, may vote.
Investors are asked to elect six directors, cast an advisory “say‑on‑pay” vote on executive compensation, and extend prior approvals that give the board flexibility to effect a reverse stock split within a specified range and to increase authorized common shares from 100,000,000 to 5,000,000,000. The agenda also includes ratifying CBIZ CPAs P.C. as independent auditor for 2026 and approving potential adjournment to solicit additional proxies if needed.
The proxy details online and telephone voting procedures, broker voting rules, and how quorum and vote thresholds are calculated. It also outlines the company’s governance structure, board committees, cybersecurity oversight, and 2025 executive pay, including salary and stock‑based awards for the CEO, Chief Innovation Officer and CFO.
Enveric Biosciences, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held via webcast. The board asks stockholders to vote on electing six directors and on proposals that include an extension to effect a reverse stock split at ratios between 1-for-5 and 1-for-50 and an extension to increase authorized common stock from 100,000,000 to 5,000,000,000 shares. Other proposals include advisory approval of executive compensation, ratification of CBIZ CPAs P.C. as auditor, and an adjournment proposal.
Enveric Biosciences is a Delaware-based biotechnology company developing next‑generation, non‑hallucinogenic neuroplastogenic drugs for psychiatric and neurological disorders. Its lead candidate, EB‑003, a DMT‑derived compound from the EVM301 Series, is in preclinical development with IND‑enabling studies planned.
The company also maintains a large psychedelic‑inspired IP library (Psybrary™) and has out‑licensed certain cannabinoid and psychedelic assets. As of June 30, 2025, non‑affiliate equity value was about $3.6 million, and the auditor has raised substantial doubt about Enveric’s ability to continue as a going concern due to recurring losses and funding needs.
Enveric Biosciences reported a net loss attributable to stockholders of $4.0 million for the quarter ended December 31, 2025, compared with a net loss of $3.2 million a year earlier. Basic and diluted loss per share was $6.12 for the quarter. The company ended 2025 with $4.7 million in cash and raised gross proceeds of $12.2 million during the year through offerings, including $4.9 million in the fourth quarter.
Subsequently, Enveric raised about $1.5 million in a registered direct offering in January 2026 and approximately $1.45 million via an at-the-market offering in February 2026. Operationally, the company advanced its lead candidate EB-003, a non-hallucinogenic neuroplastogen, by completing pre-IND dose range finding studies, achieving key manufacturing milestones, and receiving FDA feedback allowing streamlined plans for an IND submission ahead of a planned first-in-human Phase 1 trial. Enveric also strengthened its intellectual property around the EVM301 and EVM401 compound series, executed licensing agreements for cannabinoid-COX-2 conjugates, expanded a topical cannabinoid collaboration, and completed a 1-for-12 reverse stock split while relocating its headquarters to Cambridge, Massachusetts.
Enveric Biosciences filed a prospectus registering 680,620 shares of Common Stock. The registration covers up to 328,802 shares issuable upon exercise of Series G Warrants, up to 328,802 shares issuable upon exercise of Series H Warrants, and 23,016 shares issuable upon exercise of Placement Agent Warrants.
The prospectus states the Company will not receive proceeds from sales by the Selling Stockholders, but will receive net proceeds if the January 2026 Warrants are exercised for cash. The exercise prices are $4.16 for the Series G and H Warrants and $5.5125 for the Placement Agent Warrants. The document cites 1,390,335 shares outstanding as of February 4, 2026 and an assumed post‑exercise outstanding share count of 2,070,955 if all January 2026 Warrants are exercised. The prospectus notes a last reported Nasdaq sale price of $2.84 on February 4, 2026.
Enveric Biosciences, Inc. has filed an S-1 registering 680,620 shares of common stock underlying January 2026 warrants, including Series G, Series H and placement agent warrants issued in connection with a January 2026 registered direct offering and concurrent private placement.
The filing covers issuance of shares upon warrant exercise and their resale by selling stockholders. Enveric will not receive proceeds from stockholder resales, but would receive cash if the warrants are exercised at $4.16 per share for the Series G and H warrants and $5.5125 per share for the placement agent warrants, planned for product development, working capital and general corporate purposes.
The company focuses on non-hallucinogenic, neuroplastogenic small-molecule therapies, led by EB-003, and highlights significant risks, including substantial liquidity needs, going concern uncertainty, dependence on early-stage drug candidates, future dilution from equity financings and warrants, and high volatility in its Nasdaq-listed ENVB shares.
Enveric Biosciences, Inc. filed an 8-K describing that it has filed a prospectus supplement to register an additional $1,346,000 of shares of its common stock issuable under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC.
The Agreement was originally dated April 9, 2025, and Enveric has previously sold an aggregate of $1,853,878.34 of common stock through the sales agent under this arrangement. A legal opinion from Greenberg Traurig, LLP regarding the validity of the newly registered shares is included as Exhibit 5.1, with a related consent in Exhibit 23.1.
Enveric Biosciences, Inc. is launching an at-the-market stock offering of up to $1,346,000 of common stock under its existing $200 million shelf registration. The company has entered into an agreement with H.C. Wainwright & Co., which will act as sales agent.
Shares may be sold from time to time on Nasdaq or other markets at prevailing prices, with Wainwright earning a 3.0% fee on gross proceeds. If shares were sold at $2.84, the recent Nasdaq price, common stock outstanding could increase from 1,390,335 to about 1,864,278 shares.
Enveric plans to use any net proceeds primarily to develop its lead drug candidate EB-003, a non-hallucinogenic neuroplastogenic compound for difficult mental health disorders, and for general corporate purposes such as research and development, working capital, possible debt reduction, acquisitions and capital expenditures. The filing highlights risks including potential share price pressure from additional stock sales, dilution from equity and warrant overhang, and the company’s need for ongoing access to capital within Form S-3 public float limits.